Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000169186 | SCV000220428 | likely pathogenic | Hereditary fructosuria | 2014-06-19 | criteria provided, single submitter | literature only | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000169186 | SCV000916439 | likely pathogenic | Hereditary fructosuria | 2018-08-16 | criteria provided, single submitter | clinical testing | Variant summary: ALDOB c.625-2A>G is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Five predict the variant abolishes a 3 acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant was absent in 246040 control chromosomes (gnomAD). The variant, c.625-2A>G, has been reported in the literature in individuals affected with Hereditary Fructose Intolerance (Esposito_2004, Ferri_2012). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Baylor Genetics | RCV000169186 | SCV004196549 | pathogenic | Hereditary fructosuria | 2023-10-11 | criteria provided, single submitter | clinical testing | |
ATS em Genética Clínica, |
RCV000169186 | SCV001573889 | likely pathogenic | Hereditary fructosuria | 2021-03-18 | no assertion criteria provided | literature only |